Expert Rev Vaccines. 2012;11(7):791-804. The design of studies assessing prophylactic HCV vaccines in humans is challenging, since HCV incidence is low in developing countries. The selection of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results